Navigation Links
Bionomics Achieves US$1 Million Milestone Payment from Genmab
Date:2/19/2008

ADELAIDE and COPENHAGEN, Feb. 19 /PRNewswire-FirstCall/ -- Bionomics Limited (ASX: BNO, US OTC: BMICY) today announced the successful completion of pre-clinical testing on the first of eight proteins licensed to US $2.6 billion Danish antibody company Genmab A/S (OMX: GEN), triggering a US $1 million milestone payment.

Under the agreement, which was executed in February 2006, Genmab acquired the exclusive worldwide rights to eight proteins identified and characterised by Bionomics using its proprietary Angene(R) angiogenesis platform. Antibodies to these proteins have potential as treatments for cancer and other diseases. At the time of the agreement, Bionomics received an upfront fee and the US $1 million is the first in a series of potential milestone payments upon achieving specified pre-clinical and clinical milestones. Bionomics will also receive milestone payments and royalties on product sales for each product reaching the market.

The US $1 million payment has been triggered with the significant progress made in the first stage of evaluation of the licensed proteins. This evaluation strongly supported the potential of a selection of the licensed proteins as antibody targets and development of a therapy to treat pathological angiogenic conditions. This milestone marks commencement of the next phase of the development program under the collaboration.

"This is a very significant milestone for Bionomics as it validates Bionomics' Angene(R) platform as a source of new treatment modalities for cancer and other conditions involving pathological formation of new blood vessels. It also reinforces for our shareholders the significant commercial potential of our collaboration with Genmab," said CEO of Bionomics Dr. Deborah Rathjen.

"We have been working in close collaboration with Genmab for several years and this latest milestone is a clear validation of the strength of this partnership which aims to bring new antibody-based treatment
'/>"/>

SOURCE Bionomics Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
2. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
3. Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
4. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
5. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
6. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
7. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
8. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
9. BioVascular Inc. Closes $10.87 Million Series C Financing
10. Joslin Study Identifies Key Factor That Links Metabolic Syndrome; Finding May Help Millions at High Risk of Cardiovascular Disease
11. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DUBLIN , Jan. 15, 2014  Research and Markets ... "Dental Consumables Market - Global Industry Analysis, Size, ... report to their offering. (Logo: ... products which are used on patients in order to ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading health ... several new IT value-added reseller (VAR) national contracts that ... goods and services at lower costs. These include manufacturer ... such as initiative assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces that ... to the announced tender offer for all of the outstanding shares ... of the waiver, the transaction is no longer conditional on OFT ... 24, 2014 following the currently scheduled expiration time, subject to the ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
(Date:4/14/2014)... Doctors at Henry Ford Hospital reached a medical ... replacement using a novel way to access the heart. ... United States performing the unique procedure called transcaval valve ... blood vessels. , Northern Michigan resident Viola Waller, 80, ...
(Date:4/14/2014)... Penicillin, one of the scientific marvels of the 20th ... once won against bacterial infections. But scientists at the ... approach to restoring its combat effectiveness, even against so-called ... power of the penicillin family of drugs since their ...
(Date:4/14/2014)... their radiation treatment decisions leaves cancer patients feeling more ... distress around the experience, researchers from the Perelman ... report in the journal Cancer . , In ... Neha Vapiwala, MD , an associate professor in the ...
(Date:4/14/2014)... 14, 2014 Popular web information on colorectal cancer ... and doesn,t address the appropriate risks to and concerns ... gastroenterologists suggests. , In a review of a dozen ... for colorectal cancer screening were written beyond the recommended ...
(Date:4/14/2014)... Scientists found that the molecule, called microRNA 135b, is ... to drive the growth of bowel cancers. , Drugs ... of multiple cancer-causing mutations at once, while tests for ... the researchers believe. , The research was carried out ...
Breaking Medicine News(10 mins):Health News:Henry Ford Hospital hits new heart valve surgery milestone 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 3Health News:Shared decision making during radiation therapy improves patient satisfaction 2Health News:Shared decision making during radiation therapy improves patient satisfaction 3Health News:Website information on colon cancer too complex, fails to address key concerns 2Health News:Website information on colon cancer too complex, fails to address key concerns 3Health News:'MicroRNA' could be key target for bowel cancer treatment 2
... a grant of 1.6 million Euro from the Stichting ... of diabetes. The grant will make it possible to ... insulin is regulated in living organisms and this ... against diabetes. , Diabetes is an extremely common condition, ...
... University and Texas Children,s Hospital have turned stem cells from ... offers hope that such stem cells may be used to ... to come up with technology to replace defective tissue with ... the infant into the amniotic fluid," said Rice bioengineer Jeffrey ...
... Ariz. Feb. 5, 2012 The Translational Genomics ... Feb. 6-8 at the Hotel Valley Ho in Scottsdale, ... clinicians and foundations to promote the exchange of information ... The causes of childhood cancers are largely unknown ...
... not only shed its stigma, it has surpassed all ... meeting through friends, according to a new analysis of ... digital revolution in romance is a boon to lonely-hearters, ... reports the team of psychological scientists who prepared the ...
... did not decrease breast cancer cell proliferation in a ... Cancer Prevention Research , a journal of the ... A. Khan, M.D., professor of surgery at the Robert ... the results of this study are consistent with the ...
... Scientists from The Scripps Research Institute, Scripps ... the effectiveness of an advanced blood test for ... from patients, solid tumorsfrom cancer patients. The findings, ... highly sensitive blood analysis provides information that may ...
Cached Medicine News:Health News:Donation opens new opportunities for more effective diabetes treatment 2Health News:Scientists make strides toward fixing infant hearts 2Health News:Scientists make strides toward fixing infant hearts 3Health News:TGen hosts international conference for leading pediatric cancer researchers, foundations 2Health News:TGen hosts international conference for leading pediatric cancer researchers, foundations 3Health News:TGen hosts international conference for leading pediatric cancer researchers, foundations 4Health News:Online dating research shows cupid's arrow is turning digital 2Health News:Online dating research shows cupid's arrow is turning digital 3Health News:Scripps research scientists demonstrate effective new 'biopsy in a blood test' to detect cancer 2Health News:Scripps research scientists demonstrate effective new 'biopsy in a blood test' to detect cancer 3Health News:Scripps research scientists demonstrate effective new 'biopsy in a blood test' to detect cancer 4
... the active lifestyle, the Chesterfield ... for men, women and children., ... wide variety of design options, ... young, relaxed attitude, and children ...
Inquire...
... doctors, tests for elevated thyroid stimulating hormone ... the first clinical indicator of hypothyroidism. , ... to use, cost effective and accurate. ... programs and health promotion. , ThyroChek is CLIA ...
VertiGraft allografts for spine surgery deliver the strength adn performance you demand in your procedures and they are backed by quality and safety standards that are unmatched in the industry....
Medicine Products: